metaLead

metaLead, a Swiss biotechnology company, is revolutionizing the treatment landscape for metal-related diseases by developing molecular solutions that capture specific toxic metals with high selectivity and oral availability. The company is headquartered in Switzerland.

Here are key aspects of the company:

• Products & Services: metaLead develops preclinical candidates tailored to expel specific metal ions from blood and organs, offering increased efficacy over standard treatments while leaving essential metals intact.
• Industries: The company focuses on treating conditions caused by non-essential extrinsically toxic metals like lead and mercury, as well as essential but misregulated metals such as copper in Wilson disease and Menkes Disease.
• Innovation: metaLead's candidates are heavily modified to ensure stable oral administration, overcoming limitations of current standards of care regarding selectivity and depletion of specific metals without causing off-target effects.

metaLead addresses critical global health challenges by providing targeted molecular solutions for metal toxicity that offer superior safety profiles and therapeutic efficacy compared to existing medical interventions.